Travere Therapeutics, Inc. Director's Stock Transactions and Analyst Insights
Travere Therapeutics, Inc. director Roy D. Baynes recently sold 4,500 shares of common stock for a total of $209,925. The shares were sold at $46.65 each as part of a pre-established trading plan. Despite the stock trading near its 52-week high of $48.61, analysts believe it is undervalued based on InvestingPro's analysis.
Before the sale, Mr. Baynes acquired the same number of shares by exercising stock options at $18.27 per share, totaling $82,215. These options were fully vested and had an expiration date in 2031. Following these transactions, Mr. Baynes now holds 37,500 shares of Travere Therapeutics common stock.
InvestingPro Tips suggests that the company is expected to turn profitable this year after recent losses, with analysts revising earnings upwards. For investors looking for more insights, a detailed Pro Research Report on TVTX is available, offering expert analysis and actionable intelligence.
Travere Therapeutics recently announced plans to offer $400 million in convertible senior notes due in 2032, with an option for underwriters to purchase an additional $60 million in notes. Despite reporting lower-than-expected earnings per share and revenue in the first quarter of 2026, the company's stock saw an increase in aftermarket trading. These financial results and strategic activities underscore recent developments at Travere Therapeutics.
For a comprehensive analysis of TVTX and other stocks, use our Fair Value calculator, which combines 17 industry valuation models for accurate results. Discover potential hidden gems with significant upside by exploring thousands of stocks through our platform.